rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens.
Identifieur interne : 002782 ( PubMed/Corpus ); précédent : 002781; suivant : 002783rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens.
Auteurs : Angus J. Macdonald ; Long Cao ; Yuxian He ; Qian Zhao ; Shibo Jiang ; Sara LustigmanSource :
- Vaccine [ 0264-410X ] ; 2005.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (pharmacology), Animals, Antigens, Helminth (administration & dosage), Antigens, Helminth (genetics), Antigens, Helminth (immunology), Antigens, Helminth (pharmacology), HIV-1 (drug effects), HIV-1 (immunology), Helminth Proteins (pharmacology), Mice, Ovalbumin (chemistry), Ovalbumin (immunology), Recombinant Proteins (immunology), Recombinant Proteins (pharmacology), SARS Virus (drug effects), SARS Virus (immunology), Secretory Vesicles (metabolism), Th1 Cells (immunology), Th2 Cells (immunology), Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology).
- MESH :
- chemical , administration & dosage : Antigens, Helminth, Vaccines, Synthetic.
- chemical , chemistry : Ovalbumin.
- chemical , genetics : Antigens, Helminth.
- chemical , immunology : Antigens, Helminth, Ovalbumin, Recombinant Proteins, Vaccines, Synthetic.
- chemical , pharmacology : Adjuvants, Immunologic, Antigens, Helminth, Helminth Proteins, Recombinant Proteins.
- drug effects : HIV-1, SARS Virus.
- immunology : HIV-1, SARS Virus, Th1 Cells, Th2 Cells.
- metabolism : Secretory Vesicles.
- Animals, Mice.
Abstract
We studied the adjuvanticity of recombinant Onchocerca volvulus activation associated protein-1 (rOv-ASP-1) for ovalbumin (OVA) in mice. After a single immunization and one boost, rOv-ASP-1 exceeded the efficacy of alum or MPL + TDM adjuvants in terms of end-point total IgG or IgG1 and IgG2a anti-OVA titres. Using the helminth-derived adjuvant, IgG isotype responses to OVA were of a mixed Th1/Th2 profile and spleen cell cytokines exclusively Th1-type. The potent adjuvanticity of rOv-ASP-1 was confirmed in mice vaccinated with a 37-mer peptide from the S protein of SARS-CoV and an HIV-1 gp120-CD4 chimeric polypeptide antigen. Unusually for a helminth product, the rOv-ASP-1 adjuvant augmented not only Th2 but also Th1 responses, the latter property being of potential utility in stimulating anti-viral immune responses.
DOI: 10.1016/j.vaccine.2005.01.098
PubMed: 15837368
Links to Exploration step
pubmed:15837368Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens.</title><author><name sortKey="Macdonald, Angus J" sort="Macdonald, Angus J" uniqKey="Macdonald A" first="Angus J" last="Macdonald">Angus J. Macdonald</name><affiliation><nlm:affiliation>Laboratory of Molecular Parasitology, Lindsley F. Kimball Research Institute, The New York Blood Center, 310 East 67th Street, New York, NY 10021, USA. angus.macdonald@hepcgen.com</nlm:affiliation></affiliation></author><author><name sortKey="Cao, Long" sort="Cao, Long" uniqKey="Cao L" first="Long" last="Cao">Long Cao</name></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name></author><author><name sortKey="Zhao, Qian" sort="Zhao, Qian" uniqKey="Zhao Q" first="Qian" last="Zhao">Qian Zhao</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author><author><name sortKey="Lustigman, Sara" sort="Lustigman, Sara" uniqKey="Lustigman S" first="Sara" last="Lustigman">Sara Lustigman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15837368</idno><idno type="pmid">15837368</idno><idno type="doi">10.1016/j.vaccine.2005.01.098</idno><idno type="wicri:Area/PubMed/Corpus">002782</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002782</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens.</title><author><name sortKey="Macdonald, Angus J" sort="Macdonald, Angus J" uniqKey="Macdonald A" first="Angus J" last="Macdonald">Angus J. Macdonald</name><affiliation><nlm:affiliation>Laboratory of Molecular Parasitology, Lindsley F. Kimball Research Institute, The New York Blood Center, 310 East 67th Street, New York, NY 10021, USA. angus.macdonald@hepcgen.com</nlm:affiliation></affiliation></author><author><name sortKey="Cao, Long" sort="Cao, Long" uniqKey="Cao L" first="Long" last="Cao">Long Cao</name></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name></author><author><name sortKey="Zhao, Qian" sort="Zhao, Qian" uniqKey="Zhao Q" first="Qian" last="Zhao">Qian Zhao</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author><author><name sortKey="Lustigman, Sara" sort="Lustigman, Sara" uniqKey="Lustigman S" first="Sara" last="Lustigman">Sara Lustigman</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (pharmacology)</term><term>Animals</term><term>Antigens, Helminth (administration & dosage)</term><term>Antigens, Helminth (genetics)</term><term>Antigens, Helminth (immunology)</term><term>Antigens, Helminth (pharmacology)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (immunology)</term><term>Helminth Proteins (pharmacology)</term><term>Mice</term><term>Ovalbumin (chemistry)</term><term>Ovalbumin (immunology)</term><term>Recombinant Proteins (immunology)</term><term>Recombinant Proteins (pharmacology)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (immunology)</term><term>Secretory Vesicles (metabolism)</term><term>Th1 Cells (immunology)</term><term>Th2 Cells (immunology)</term><term>Vaccines, Synthetic (administration & dosage)</term><term>Vaccines, Synthetic (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antigens, Helminth</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Ovalbumin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antigens, Helminth</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Helminth</term><term>Ovalbumin</term><term>Recombinant Proteins</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Antigens, Helminth</term><term>Helminth Proteins</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV-1</term><term>SARS Virus</term><term>Th1 Cells</term><term>Th2 Cells</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Secretory Vesicles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Mice</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We studied the adjuvanticity of recombinant Onchocerca volvulus activation associated protein-1 (rOv-ASP-1) for ovalbumin (OVA) in mice. After a single immunization and one boost, rOv-ASP-1 exceeded the efficacy of alum or MPL + TDM adjuvants in terms of end-point total IgG or IgG1 and IgG2a anti-OVA titres. Using the helminth-derived adjuvant, IgG isotype responses to OVA were of a mixed Th1/Th2 profile and spleen cell cytokines exclusively Th1-type. The potent adjuvanticity of rOv-ASP-1 was confirmed in mice vaccinated with a 37-mer peptide from the S protein of SARS-CoV and an HIV-1 gp120-CD4 chimeric polypeptide antigen. Unusually for a helminth product, the rOv-ASP-1 adjuvant augmented not only Th2 but also Th1 responses, the latter property being of potential utility in stimulating anti-viral immune responses.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15837368</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>26</Issue><PubDate><Year>2005</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens.</ArticleTitle><Pagination><MedlinePgn>3446-52</MedlinePgn></Pagination><Abstract><AbstractText>We studied the adjuvanticity of recombinant Onchocerca volvulus activation associated protein-1 (rOv-ASP-1) for ovalbumin (OVA) in mice. After a single immunization and one boost, rOv-ASP-1 exceeded the efficacy of alum or MPL + TDM adjuvants in terms of end-point total IgG or IgG1 and IgG2a anti-OVA titres. Using the helminth-derived adjuvant, IgG isotype responses to OVA were of a mixed Th1/Th2 profile and spleen cell cytokines exclusively Th1-type. The potent adjuvanticity of rOv-ASP-1 was confirmed in mice vaccinated with a 37-mer peptide from the S protein of SARS-CoV and an HIV-1 gp120-CD4 chimeric polypeptide antigen. Unusually for a helminth product, the rOv-ASP-1 adjuvant augmented not only Th2 but also Th1 responses, the latter property being of potential utility in stimulating anti-viral immune responses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>MacDonald</LastName><ForeName>Angus J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Parasitology, Lindsley F. Kimball Research Institute, The New York Blood Center, 310 East 67th Street, New York, NY 10021, USA. angus.macdonald@hepcgen.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Long</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yuxian</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Qian</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Shibo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lustigman</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI04328</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000947">Antigens, Helminth</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015801">Helminth Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C414408">Ov-ASP-1 protein, Onchocerca volvulus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>9006-59-1</RegistryNumber><NameOfSubstance UI="D010047">Ovalbumin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000947" MajorTopicYN="N">Antigens, Helminth</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015801" MajorTopicYN="N">Helminth Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010047" MajorTopicYN="N">Ovalbumin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022142" MajorTopicYN="N">Secretory Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018418" MajorTopicYN="N">Th2 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>08</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>01</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15837368</ArticleId><ArticleId IdType="pii">S0264-410X(05)00148-9</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2005.01.098</ArticleId><ArticleId IdType="pmc">PMC7115491</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>AIDS Res Hum Retroviruses. 1993 May;9(5):431-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8318269</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2003 Dec 15;171(12):6723-32</Citation><ArticleIdList><ArticleId IdType="pubmed">14662876</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Immunol. 2003 Sep;3(9):733-44</Citation><ArticleIdList><ArticleId IdType="pubmed">12949497</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Infect Immun. 2002 Nov;70(11):6058-67</Citation><ArticleIdList><ArticleId IdType="pubmed">12379682</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 Dec;74(24):11427-36</Citation><ArticleIdList><ArticleId IdType="pubmed">11090138</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Parasite Immunol. 2004 Jan;26(1):53-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15198646</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Immunol. 1995;13:151-77</Citation><ArticleIdList><ArticleId IdType="pubmed">7612219</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Mar 20;363(9413):938-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15043961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunol Lett. 2004 Jun 15;94(1-2):27-33</Citation><ArticleIdList><ArticleId IdType="pubmed">15234531</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2001 Jul 1;167(1):442-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11418681</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2004 Mar 1;189(5):919-29</Citation><ArticleIdList><ArticleId IdType="pubmed">14976610</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Biochem Parasitol. 2000 Jul;109(2):91-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10960168</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Res Vet Sci. 2002 Dec;73(3):297-306</Citation><ArticleIdList><ArticleId IdType="pubmed">12443689</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Immunol. 2000 Jul;30(7):1977-87</Citation><ArticleIdList><ArticleId IdType="pubmed">10940887</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Parasitol. 2001 Jul;31(9):889-98</Citation><ArticleIdList><ArticleId IdType="pubmed">11406138</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2003 Oct 1;21(27-30):4421-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14505925</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2003 Aug 15;171(4):2127-33</Citation><ArticleIdList><ArticleId IdType="pubmed">12902519</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Parasitol. 2003 Sep 30;33(11):1245-58</Citation><ArticleIdList><ArticleId IdType="pubmed">13678639</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002782 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002782 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15837368
|texte= rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15837368" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |